233 related articles for article (PubMed ID: 31942031)
21. A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.
Matossian MD; Burks HE; Bowles AC; Elliott S; Hoang VT; Sabol RA; Pashos NC; O'Donnell B; Miller KS; Wahba BM; Bunnell BA; Moroz K; Zea AH; Jones SD; Ochoa AC; Al-Khami AA; Hossain F; Riker AI; Rhodes LV; Martin EC; Miele L; Burow ME; Collins-Burow BM
Breast Cancer Res Treat; 2018 Jun; 169(2):381-390. PubMed ID: 29392581
[TBL] [Abstract][Full Text] [Related]
22. CD24 negativity reprograms mitochondrial metabolism to PPARα and NF-κB-driven fatty acid β-oxidation in triple-negative breast cancer.
Murthy D; Dutta D; Attri KS; Samanta T; Yang S; Jung KH; Latario SG; Putluri V; Huang S; Putluri N; Park JH; Kaipparettu BA
Cancer Lett; 2024 Apr; 587():216724. PubMed ID: 38373689
[TBL] [Abstract][Full Text] [Related]
23. New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription.
Hu MH; Wu TY; Huang Q; Jin G
Nucleic Acids Res; 2019 Nov; 47(20):10529-10542. PubMed ID: 31584090
[TBL] [Abstract][Full Text] [Related]
24. The long noncoding RNA sONE represses triple-negative breast cancer aggressiveness through inducing the expression of miR-34a, miR-15a, miR-16, and let-7a.
Youness RA; Hafez HM; Khallaf E; Assal RA; Abdel Motaal A; Gad MZ
J Cell Physiol; 2019 Nov; 234(11):20286-20297. PubMed ID: 30968427
[TBL] [Abstract][Full Text] [Related]
25. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.
Shen L; O'Shea JM; Kaadige MR; Cunha S; Wilde BR; Cohen AL; Welm AL; Ayer DE
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5425-30. PubMed ID: 25870263
[TBL] [Abstract][Full Text] [Related]
26. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
27. G protein-coupled kisspeptin receptor induces metabolic reprograming and tumorigenesis in estrogen receptor-negative breast cancer.
Dragan M; Nguyen MU; Guzman S; Goertzen C; Brackstone M; Dhillo WS; Bech PR; Clarke S; Abbara A; Tuck AB; Hess DA; Pine SR; Zong WX; Wondisford FE; Su X; Babwah AV; Bhattacharya M
Cell Death Dis; 2020 Feb; 11(2):106. PubMed ID: 32034133
[TBL] [Abstract][Full Text] [Related]
28. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
Zhang S; Chung WC; Miele L; Xu K
Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
[TBL] [Abstract][Full Text] [Related]
29. Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer.
Jian Y; Huang X; Fang L; Wang M; Liu Q; Xu H; Kong L; Chen X; Ouyang Y; Wang X; Wei W; Song L
J Exp Clin Cancer Res; 2021 Feb; 40(1):56. PubMed ID: 33541412
[TBL] [Abstract][Full Text] [Related]
30. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
[TBL] [Abstract][Full Text] [Related]
31. Inhibition effect of exosomes-mediated Let-7a on the development and metastasis of triple negative breast cancer by down-regulating the expression of c-Myc.
Du J; Fan JJ; Dong C; Li HT; Ma BL
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5301-5314. PubMed ID: 31298382
[TBL] [Abstract][Full Text] [Related]
32. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
33. Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.
Wang E; Sorolla A; Cunningham PT; Bogdawa HM; Beck S; Golden E; Dewhurst RE; Florez L; Cruickshank MN; Hoffmann K; Hopkins RM; Kim J; Woo AJ; Watt PM; Blancafort P
Oncogene; 2019 Jan; 38(1):140-150. PubMed ID: 30076412
[TBL] [Abstract][Full Text] [Related]
34. HRD1 inhibits fatty acid oxidation and tumorigenesis by ubiquitinating CPT2 in triple-negative breast cancer.
Guo X; Wang A; Wang W; Wang Y; Chen H; Liu X; Xia T; Zhang A; Chen D; Qi H; Ling T; Piao HL; Wang HJ
Mol Oncol; 2021 Feb; 15(2):642-656. PubMed ID: 33207079
[TBL] [Abstract][Full Text] [Related]
35. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
36. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells.
Yin S; Cheryan VT; Xu L; Rishi AK; Reddy KB
PLoS One; 2017; 12(8):e0183578. PubMed ID: 28817737
[TBL] [Abstract][Full Text] [Related]
37. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
38. Microelectrode bioimpedance analysis distinguishes basal and claudin-low subtypes of triple negative breast cancer cells.
Srinivasaraghavan V; Strobl J; Agah M
Biomed Microdevices; 2015 Aug; 17(4):80. PubMed ID: 26216474
[TBL] [Abstract][Full Text] [Related]
39. The requirement for cyclin E in c-Myc overexpressing breast cancers.
Zhou Y; Geng Y; Zhang Y; Zhou Y; Chu C; Sharma S; Fassl A; Butter D; Sicinski P
Cell Cycle; 2020 Oct; 19(20):2589-2599. PubMed ID: 32975478
[TBL] [Abstract][Full Text] [Related]
40. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
